Skip to main content
    R

    Repligen Corporation (RGEN)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $184.17
    +5.97 (+3.35%)

    Market Cap: $11.31B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    90%(35/39)
    Avg Surprise
    +19.18%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.46
    Range$0.41 - $0.48
    17 analysts
    EPS RevisionsNo revisions (7d)
    7
    6
    30d
    EPS Estimate DriftChange to current
    90d ago$0.47-2.6%
    60d ago$0.46-0.5%
    30d ago$0.46-0.4%
    7d ago$0.46-0.0%
    Current$0.46
    Revenue Consensus
    $207M
    Range$205M - $208M
    17 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.77
    Range$0.74 - $0.79
    20 analysts
    Revenue Consensus
    $227M
    Range$218M - $256M
    20 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.77---
    Sep 26EST
    		-$0.46---
    Jun 26
    Reported Jul 28
    		$0.54$0.45+20.00%Beat+45.9%
    Mar 26
    Reported May 5
    		$0.48$0.39+23.08%Beat+23.1%
    Dec 25
    Reported Feb 24
    		$0.49$0.44+11.52%Beat+11.4%
    Sep 25
    Reported Oct 28
    		$0.46$0.41+12.20%Beat+4031.6%
    Jun 25
    Reported Jul 29
    		$0.37$0.39-5.13%Miss+12.1%
    Mar 25
    Reported Apr 29
    		$0.39$0.35+11.43%Beat+39.3%
    Dec 24
    Reported Feb 20
    		$0.44$0.42+4.99%Beat+33.3%
    Sep 24
    Reported Nov 12
    		$-0.01N/A-103.55%Miss-105.1%
    Jun 24
    Reported Jul 30
    		$0.33$0.33+0.00%Beat-37.7%
    Mar 24
    Reported May 1
    		$0.28$0.30-6.67%Miss-56.3%
    Dec 23
    Reported Feb 21
    		$0.33$0.33+0.00%Beat-51.5%
    Sep 23
    Reported Oct 31
    		$0.23$0.16+43.75%Beat-70.1%
    Jun 23
    Reported Aug 2
    		$0.53$0.48+10.42%Beat-41.8%
    Mar 23
    Reported May 2
    		$0.64$0.59+8.47%Beat-30.4%
    Dec 22
    Reported Feb 22
    		$0.68$0.58+17.24%Beat-16.0%
    Sep 22
    Reported Nov 1
    		$0.77$0.68+13.24%Beat-1.3%
    Jun 22
    Reported Aug 2
    		$0.91$0.71+28.17%Beat+15.2%
    Mar 22
    Reported Apr 27
    		$0.92$0.72+27.78%Beat+35.3%
    Dec 21
    Reported Feb 17
    		$0.81$0.65+24.62%Beat+55.8%
    Sep 21
    Reported Oct 28
    		$0.78$0.64+21.88%Beat+95.0%
    Jun 21
    Reported Jul 27
    		$0.79$0.52+51.92%Beat+88.1%
    Mar 21
    Reported May 4
    		$0.68$0.42+61.90%Beat+112.5%
    Dec 20
    Reported Feb 24
    		$0.52$0.31+67.74%Beat+160.0%
    Sep 20
    Reported Nov 5
    		$0.40$0.28+42.86%Beat+53.8%
    Jun 20
    Reported Jul 30
    		$0.42$0.28+50.00%Beat+35.5%
    Mar 20
    Reported May 6
    		$0.32$0.21+52.38%Beat+14.3%
    Dec 19
    Reported Feb 20
    		$0.20$0.18+11.11%Beat-4.8%
    Sep 19
    Reported Oct 31
    		$0.26$0.19+36.84%Beat+30.0%
    Jun 19
    Reported Aug 1
    		$0.31$0.30+3.33%Beat+93.8%
    Mar 19
    Reported May 9
    		$0.28$0.22+27.27%Beat+64.7%
    Dec 18
    Reported Feb 21
    		$0.21$0.21+0.00%Beat+5.0%
    Sep 18
    Reported Nov 1
    		$0.20$0.18+11.11%Beat+33.3%
    Jun 18
    Reported Aug 2
    		$0.16$0.18-11.11%Miss-20.0%
    Mar 18
    Reported May 8
    		$0.17$0.15+13.33%Beat+13.3%
    Dec 17
    Reported Feb 22
    		$0.20$0.12+66.67%Beat+150.0%
    Sep 17
    Reported Nov 9
    		$0.15$0.11+36.36%Beat-
    Jun 17
    Reported Aug 3
    		$0.20$0.15+33.33%Beat-
    Mar 17
    Reported May 4
    		$0.15$0.13+15.38%Beat-
    Dec 16
    Reported Feb 22
    		$0.08$0.07+14.29%Beat-

    Key Metrics

    Valuation
    P/E Ratio93.49EV/EBITDA67.37x
    Price/FCF92.80xFCF Yield1.08%
    Profitability
    Profit Margin5.29%Operating Margin9.31%
    ROE1.99%ROIC1.43%
    Financial Health
    Debt/Equity0.26xInterest Coverage2.16x
    Current Ratio9.05xQuick Ratio7.64x
    Trading Statistics
    Beta1.08Avg Volume1.32M
    52-Week High$198.8752-Week Low$100.99

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$176.13
    SMA 20$181.43
    SMA 50$175.46
    SMA 200$144.08
    EMA 10$177.81
    EMA 20$178.00
    EMA 50$171.93
    EMA 200$150.62

    MACD

    Line: 0.62Signal: 1.41Hist: -0.79

    ADX

    ADX: 25.6+DI: 28.8-DI: 19.8

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down80.0
    PSAR$157.44

    Bollinger Bands

    Upper Band$199.14
    Lower Band$163.72
    %B Position1952%(Upper)
    Band Width0.58

    RSI (14-Day)

    Neutral
    55.5

    Momentum Oscillators

    Stoch %K52.7
    Stoch %D45.3
    Williams %R-35.5
    ROC (10d)3.9%
    Momentum6.94
    CCI (20d)11.4
    MFI (14d)51.7

    Volatility Measures

    ATR (14d)$8.46(4.6%)
    StdDev (20d)8.85
    Hist Vol58.5%(High)

    Volume Flow

    VWAP$182.55
    OBV17.3M
    AD Line-9.8M
    CMF (20d)0.023

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.8x
    VWMA (20d)$180.71

    Pivot Points

    R3$186.72
    R2$183.90
    R1$181.05
    Pivot Point$178.22
    S1$175.37
    S2$172.54
    S3$169.69

    Advanced Oscillators

    TSI1.93
    Ultimate Osc56.7
    KST17.40

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$204.13M$194.25M$197.91M$188.81M$182.37M$169.17M$167.55M$154.87M$158.84M$153.18M$166.62M$141.19M
    Cost of Revenue$94.09M$85.97M$94.08M$88.29M$89.37M$77.80M$128.71M$77.38M$77.31M$76.39M$88.14M$104.63M
    Gross Profit$110.04M$108.28M$103.83M$100.52M$93.00M$91.37M$38.84M$77.49M$81.53M$76.79M$78.48M$36.56M
    Operating Expenses$96.06M$92.34M$85.96M$83.69M$79.10M$84.79M$75.34M$85.32M$76.06M$73.04M$68.61M$31.87M
    R&D$14.42M$14.46M$13.12M$14.18M$13.97M$12.11M$11.68M$9.71M$10.57M$11.24M$10.29M$10.58M
    SG&A$76.62M$76.54M$74.36M$73.66M$70.91M$70.71M$60.47M$75.61M$65.48M$61.80M$57.63M$55.58M
    Operating Income$13.98M$15.94M$17.87M$16.82M$13.90M$6.58M$-36,501,000$-7,832,000$5.47M$3.75M$9.87M$4.69M
    Interest Income$6.43M$6.34M$6.75M$6.92M$6.58M$7.31M$8.29M$9.13M$9.41M$8.99M$6.02M$6.66M
    Interest Expense$5.66M$5.58M$5.50M$5.41M$5.35M$5.25M$5.46M$5.12M$5.12M$5.03M$13.95M$408,000
    Income Before Tax$14.15M$1.77M$19.11M$17.11M$18.21M$7.94M$-38,608,000$-1,149,000$9.03M$3.69M$1.86M$11.38M
    Income Tax Expense$9.14M$-6,561,000$5.83M$2.20M$3.35M$2.11M$-4,739,000$-495,000$3.31M$399,000$18.32M$-5,542,000
    Net Income$5.01M$8.33M$13.29M$14.91M$14.87M$5.83M$-33,869,000$-654,000$5.71M$3.30M$-16,450,000$16.92M
    EBITDA$41.62M$29.92M$27.45M$54.45M$45.87M$33.11M$-19,112,000$7.45M$29.95M$24.84M$28.13M$25.64M
    EBIT$13.38M$1.01M$17.85M$15.61M$16.98M$5.88M$-41,439,000$-5,157,000$4.73M$-269,000$9.79M$5.13M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RGEN

    Government Contracts

    Gov Obligations (TTM)
    $174560
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    1
    Avg Remaining Term
    107.6 mo

    Top agency: Department of Health and Human Services at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    75F40126P00067Department of Health and Human ServicesFood and Drug Administration$174560May 28, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Repligen Corp (RGEN) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 85/100

    Repligen Corp (RGEN) stock increased by 3.4%, but GuruFocus's GF Value™ indicates it is 1.9% overvalued at $184.17 compared to its intrinsic value estimate of $180.67. Despite a strong GF Score™ of 85/100 and positive...

    GuruFocus•10/15/26•Somewhat-Bearish

    Repligen Corporation (RGEN) Stock Forecasts

    This article provides a stock forecast for Repligen Corporation (RGEN), a global life sciences company specializing in bioprocessing equipment. It highlights an "Upgrade" prompt for premium research reports...

    Yahoo Finance•10/15/26•Neutral

    Repligen to Report Third Quarter 2026 Financial Results

    Repligen Corporation announced it will report its third quarter 2026 financial results on Tuesday, October 27, 2026. The company will issue a press release before market open and will host a conference call at 8:00 a.m....

    GlobeNewswire•10/13/26•Neutral

    A company behind systems used to make biological drugs will discuss results Oct. 27. Repligen's call starts at 8 a.m.

    Repligen (RGEN) announced it will report its third-quarter 2026 financial results before the market opens on October 27...

    Stock Titan•10/13/26•Neutral

    Repligen to Report Third Quarter 2026 Financial Results

    Repligen Corporation announced it will report its third quarter 2026 financial results on Tuesday, October 27, 2026. The company will issue a press release before market open and host a conference call at 8:00 a.m. ET...

    GlobeNewswire•10/13/26•Neutral

    RGEN Valuation and Fair Value

    P/E
    93.5x
    Forward P/E
    67.1x
    EV/EBITDA
    67.4x
    P/FCF
    92.8x
    PEG
    1.8x
    P/B
    4.9x
    See GNG's fair value

    RGEN Profitability: Margins, ROIC and FCF

    Gross margin
    53.8%
    Operating margin
    9.3%
    Net margin
    5.3%
    ROIC
    1.4%
    ROE
    2.0%
    FCF margin
    14.3%
    FCF yield
    1.1%

    RGEN Competitors

    CompanyTicker
    Bio-Techne CorpTECH
    Elanco Animal HealthELAN
    DaVita HealthCare Partners IncDVA
    Fresenius Medical Care CorporationFMS
    Smith & Nephew SNATS IncSNN
    Vaxcyte IncPCVX
    Tempus AI, Inc. Class A Common StockTEM
    Universal Health Services IncUHS

    Sector: Healthcare

    RGEN Analyst Ratings

    Consensus
    Buy
    Analysts
    22
    Strong Buy
    3
    Buy
    15
    Hold
    4
    Sell
    0
    Strong Sell
    0

    RGEN Bull Case vs Bear Case

    Bull case

    • RGEN beat EPS estimates in 75.0% of its last 8 reported quarters.
    • RGEN grew quarterly revenue 11.9% year over year.
    • 81.8% of RGEN's analyst ratings are Buy or Strong Buy.

    Bear case

    • RGEN trades at 93.5x trailing earnings.

    RGEN Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    -3.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.46
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    7 up, 6 down

    Frequently Asked Questions About RGEN

    Does RGEN pay dividends?

    Repligen Corporation (RGEN) does not currently pay a regular dividend.

    What is RGEN's P/E ratio?

    Repligen Corporation has a price-to-earnings (P/E) ratio of 93.49.

    What is RGEN's market cap?

    Repligen Corporation (RGEN) has a market capitalization of $11.31B with a current stock price of $184.17.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In